Article · Volume 15, Issue 2 · pp. 292–297
In vitro and in vivo Antidiabetic Evaluation of Synthesised Novel New Chromane and its Derivatives
Sonia Kamboj1,2, Jasmine Chaudhary1, Akash Jain1, Randhir Singh3
- 1Department of Pharmaceutical Sciences, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Haryana, INDIA.
- 2Department of Pharmaceutical Sciences, Ch. Devi Lal College of Pharmacy, Jagadhri, Haryana, INDIA.
- 3Department of Pharmacology, Central University of Punjab, Bathinda, Punjab, INDIA.
Abstract
Background: To evaluate biological activity of synthesised new chromane and its analogues.Materials and Methods: New chromane {3,5,7-trihydroxy 2-(4-hydroxy benzyl) chroman-4-one} isolated from dried leaves of Dillenia indica Linn., family Dilleniaceae is structurally relating with various reported chroman-4-one derivatives displaying remarkable in vivo antidiabetic activity. But the literature reveals that 0.8 – 1.0% yield of pure new chromane was obtained in isolation. Following reported literature data of synthesis and in silico study; Synthesized new chromane and its derivatives (S23-S32) were investigated for in vitro (α-amylase and α-glucosidase) as well as in vivo antidiabetic evaluation respectively. Result and Conclusion:in vitro hypoglycaemic study also displayed the significant antidiabetic potential of new chromane and its O-alkyl substituents (especially S23) while other synthesized compounds (S27-S32) reported for moderate to mild effects w.r.t. reference drug (acarbose). Moreover, synthetic new chromane and O-alkyl substituent (S23) exhibited maximum antidiabetic activity also in terms of lowering glucose concentration while others (S27-S32) showed mild anti-diabetic effect in comparison to reference drug (metformin).
Keywords: α-amylase; α-glucosidase; Chromane; Antidiabetic; Hypoglycaemic; Streptozotacin
The full text of this article is available as a PDF. Open the PDF.